United States: Court Strikes FDA Preapproval For Tobacco Product Labeling Changes

Last Updated: August 31 2016
Article by Kathleen M. Sanzo and Heather A. Dorsey

Court holds that FDA guidance cannot require preapproval for label modifications to existing tobacco products, but can require preapproval for quantity modifications.

On August 16, the US District Court for the District of Columbia issued an opinion1 striking part of the US Food and Drug Administration's (FDA's) Guidance for Industry, Demonstrating the Substantial Equivalence of a New Product: Responses to Frequently Asked Questions (Edition 2) (Final Guidance).2

The court held that under the Family Smoking Prevention and Tobacco Control Act (TCA), a modification to an existing tobacco product label does not result in a "new tobacco product"3 and therefore does not require FDA preapproval through a showing of substantial equivalence (SE). Consequently, the court vacated the section of the FDA Guidance that requires a showing of SE for an existing tobacco product labeling change, but upheld the section that requires SE preapproval for product quantity changes because the physical characteristics of the product are altered, which results in a "new tobacco product" under the TCA.

While the court defines "existing products" as those commercially marketed before February 15, 2007, its holding appears to generally affect all tobacco products that are legally marketed (i.e., those addressed by the Final Guidance):

"The court therefore vacates that portion of the Second SE Guidance relating to a labeling change, but affirms that portion relating to a product-quantity change."4

It is unclear how FDA will interpret the decision as it applies to products marketed after February 15, 2007 and whether FDA will interpret the decision to apply broadly to all products covered by the Guidance or only to those existing products marketed before February 15, 2007.

The language of the opinion is not limited to any particular "tobacco product" and appears applicable to all "tobacco products," including "newly deemed" tobacco products (i.e., e-cigarettes, cigars, etc.).5 For more information on newly deemed tobacco products, read our May 2016 LawFlash, " FDA Finalizes Tobacco Products Rule."


In September 2011, FDA issued a document titled "Draft Guidance for Industry and FDA Staff: Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions" (Draft Guidance). The Draft Guidance provided FDA's thinking regarding when a label change resulted in a "new tobacco product." It stated that SE preapproval was required when a label change to an existing tobacco product resulted in a "distinct" product such that customers would believe the product to be different from the existing product. In such cases, the manufacturer would be able to submit a "Same Characteristics SE Report"—an abbreviated SE submission. The Draft Guidance provided a chart of examples as to when a change might result in a distinct product. For example, a change in background color from red to green "may" have resulted in a "distinct product," however, a change in background color from white to cream "may not" have resulted in a "distinct product." Similarly, the chart stated that a change in a logo image (e.g., from a star to a lion) "may" have resulted in a "distinct product," but that a change in the logo size "may not" have resulted in a "distinct product."

Thus, tobacco product manufacturers were left to determine when label changes "may" or "may not" result in a "distinct product" such that it was a "new tobacco product" requiring FDA's SE preapproval prior to marketing.

The Draft Guidance also addressed the impact of a change in product quantity in a tobacco product. FDA stated that a change in product quantity would constitute a "new tobacco product" under the TCA because the characteristics of the tobacco products (e.g., the amount of ingredients) changed. For example, a change in the number of portioned parts per package (e.g., 20 to 24 cigarettes in a pack) or a change in the weight of a product (e.g., a one-ounce to a two-ounce tin of smokeless tobacco) would constitute a product quantity change such that the product would be a "new tobacco product" requiring an SE preapproval submission—a "Product Quantity Change SE Report."

On September 8, 2015, FDA released a revised, final version of the Guidance. The Final Guidance offered the same content, but new justifications for FDA's position as to how label and quantity changes could result in a "new tobacco product."

On September 30, 2015, a number of large tobacco companies filed suit challenging FDA's position that a label modification or a quantity change creates a "new tobacco product" triggering the SE preapproval review process.

Label Modification Provision Vacated

The court held that FDA's reasoning that a labeling modification to an existing product requires an SE preapproval is inconsistent with the intent of the TCA and the Food, Drug and Cosmetic Act (FDCA). The court states in its recent decision that the intent of the US Congress is clear from the plain text and structure of the TCA: First, Congress purposefully chose to omit the word "label" and its iterations from the definition of "new tobacco product." The words "label" or "labeling" were used no less than 150 times in the TCA, but were omitted from the definition of "new tobacco product." Instead, Congress chose to define "new tobacco product" and "tobacco product" in terms of physical attributes.

Furthermore, Congress did not use the terms "label" or "labeling" in its SE provisions—Sections 905(j) and 910(a) of the FDCA—and therefore, the court held, Congress did not intend for a label change to trigger the SE preapproval requirement. Thus, the court vacated the provisions of the Final Guidance that state that a label change results in a "new tobacco product."

In its analysis, the court examined the Medical Device Amendments (MDA) to the FDCA, as the SE provisions of the TCA were largely modeled on those in the MDA. The court read the TCA and MDA provisions congruently, stating that it is appropriate to presume that Congress intended the text to have the same meaning in both statutes.

Quantity Modifications Provision Upheld

The court examined the plain language of the TCA and the definition of "new tobacco product" in its analysis of the quantity modification terms in the Final Guidance. The court states that because Section 910 of the FDCA states that "any modification . . . of a tobacco product" creates a "new tobacco product," even the slightest change to the physical components of the existing tobacco product would result in a "new tobacco product" and require a showing of SE prior to marketing. Thus, the court states, "an increase or decrease in quantity necessarily entails a change in the amount of the constituent ingredients and additives within a tobacco product, including nicotine."

Furthermore, Congress indicated that a major motivation behind the TCA was to reduce youth consumption of tobacco products. The Final Guidance relies upon how the quantity or size of a tobacco product can affect tobacco consumption by youth (e.g., barriers to initiation, lowered product harm perceptions). Thus, according to the court, the TCA text, structure, and purpose demonstrate that a change in product quantity results in a "new tobacco product" requiring FDA SE preapproval.

Key Takeaways

  • FDA's prior guidance that labeling changes to existing products create a "new tobacco product" such that a showing of SE is required prior to marketing under the TCA has been vacated.
  • FDA's position that product quantity changes create a "new tobacco product" such that a showing of SE is required prior to marketing has been upheld.
  • Manufacturers may be able to submit a Product Quantity Change SE Report for simple changes in product quantities.


1. Philip Morris USA Inc., v. FDA, Case No. 1:15-cv-01590 (D.D.C. Aug. 16, 2016).

2. US Food & Drug Admin., Guidance for Industry, Demonstrating the Substantial Equivalence of a New Product: Responses to Frequently Asked Questions (Edition 2) (Sept. 2015) http://www.fda.gov/downloads/TobaccoProducts/Labeling/RulesRegulationsGuidance/UCM436468.pdf.

3. See Food Drug & Cosmetic Act (FDCA) § 910(a)(1).

4. Philip Morris, Case No. 1:15-cv-01590, at 43.

5. See Deeming Tobacco Products to be Subject to the Federal Food, Drug and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products; Final Rule, 81 Fed. Reg. 28974 (May 10, 2016).

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions